


SR-0813

Cat. No.:	HY-145409		
CAS No.:	2597186-19-9		
Molecular Formula:	C ₂₅ H ₃₂ N ₆ O ₃ S		
Molecular Weight:	496.62		
Target:	Epigenetic Reader Domain		
Pathway:	Epigenetics		
Storage:	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	6 months
		-20°C	1 month



SOLVENT & SOLUBILITY

In Vitro

DMSO : 100 mg/mL (201.36 mM; Need ultrasonic)

Concentration	Mass		
	1 mg	5 mg	10 mg
1 mM	2.0136 mL	10.0681 mL	20.1361 mL
5 mM	0.4027 mL	2.0136 mL	4.0272 mL
10 mM	0.2014 mL	1.0068 mL	2.0136 mL

Please refer to the solubility information to select the appropriate solvent.

BIOLOGICAL ACTIVITY

Description

SR-0813 is a potent and selective ENL/AF9 YEATS domain inhibitor. SR-0813 has IC₅₀ and EC₅₀ values of 25 nM and 205 nM for ENL YEATS domain, respectively. SR-0813 has IC₅₀ and EC₅₀ values of 311 nM and 76 nM (CETSA) for AF9 YEATS domain, respectively. SR-0813 binds MAP3K19 with over 100-fold lower affinity (K_d=3.5 μM) than ENL YEATS (K_d=30 nM). SR-0813 can be used for the research of acute leukemia^[1].

IC₅₀ & Target

ENL YEATS domain 25 nM (IC ₅₀)	ENL YEATS domain 205 nM (EC ₅₀)	AF9 YEATS domain 311 nM (IC ₅₀)	AF9 YEATS domain 76 nM (EC ₅₀)
ENL YEATS domain 30 nM (K _d)	MAP3K19 3.5 μM (K _d)		

In Vitro

SR-0813 (compound 10; 0, 1, 10 μM; 4 h) dose-dependent evicts ENL from known ENL binding sites, including the HOXA10 gene body and MYB promoter in MV4;11 cells^[1].
SR-0813 (0, 1, 10 μM; 0, 24, 48, 72 h) downregulates the transcript levels of HOXA9, MEIS1, and MYC, and increases the abundance of the ITGAM transcript in MV4;11 cells^[1].

SR-0813 (0, 1, 10 μ M; approximately 2 weeks) inhibits the growth of multiple lineage leukemia (MLL)-fusion leukemia cell lines (MV4;11, MOLM-13, OCI/AML-2) and HB11;19 cells^[1].

SR-0813 (1 μ M, 4h) does not elicit global changes in gene expression in MV4;11 cells, but produces a strikingly selective suppression of ENL target genes^[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Proliferation Assay^[1]

Cell Line:	MLL-fusion leukemia cell lines: MV4;11 (MLL-AF4 AML), MOLM-13 (MLL-AF9 AML), and OCI/AML-2 (MLL-AF6 AML), which are sensitive to the genetic loss of ENL. HB11;19 cells, which harboring an MLL-ENL fusion.
Concentration:	0, 1, 10 μ M
Incubation Time:	Approximately 2 weeks
Result:	Inhibited the growth of cells.

REFERENCES

[1]. Garnar-Wortzel L, et al. Chemical Inhibition of ENL/AF9 YEATS Domains in Acute Leukemia. ACS Cent Sci. 2021 May 26;7(5):815-830.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA